Article PDF
Avoid common mistakes on your manuscript.
References
Lewis RA, Austen KF, Soberman RJ. Leukotrienes and other products of the 5-lipoxygenase pathway. N Engl J Med 1990;323:645–655.
Bentley AM, Jacobson MR, Cumberworth V, et al. Immunohistology of the nasal mucosa in seasonal allergic rhinitis: Increases in activated eosinophils and epithelial mast cells. J Allergy Clin Immunol 1992;89:877–883.
Igarashi Y, White M, Hausfeld J, Irani A, Schwartz L, Kaliner M. IgE-positive cells in nasal mucosa are mostly mast cells. FASEB J 1992;6:A2005. (Abstract).
Drettner B, Aust R. Plethysmographic studies of the blood flow in the mucosa of the human maxillary sinus. Acta Otolaryngol 1974;78:259–265.
Drazen JM, Austen KF, Lewis RA, Clark: DA, Gota G, Marfat A. Comparative airway in vascular activities of leukotrienes C4 and D m_Q and in vitro. Proc Natl Acad Sci USA 1980;77:4354–4358.
Powell WS, Chung D, Gravel S. 5-Os<∼6,8,11,1 (eicosatetraenoic acid is a potent stimulator of human eosinophil migration. J Immunol 1995;154:4123–4132.
Naderio RM, Meier HL, Kagey-Sobotka A, et al. Mediator release after nasal airway challenge with allergin. Am Rev Respir Dis 1983;128:597–602.
Creticos PS, Peters SP, Adkinson NF, Jr., et al. Peptide leukotriene release after antigen challenge in patients sensitive to ragweed. N Engl J Med 1984;310:1626–1630.
Pipkorn U, Proud D, Lichtenstein LM, et al. Affect of short-term systemic leukocorticoid treatment on human nasal mediator-release after antigen challenge. J Clin Invest 1987;80:957–961.
Shaw RJ, Fitzharris P, Cromwell O, Wardlaw AJ, Kay AB. Allergen-induced release of sulphidopeptide leukotrienes (SRS-A) and LTB 4 in allergic rhinitis. Allergy 1985;40:1–6.
Miadonna A, Tedeschi A, Leggieri E, et al. Behavior and clinical relevance of histamine and leukotriene C4 and B4 in grass- and pollen-induced rhinitis. Am Rev Respir Dis 1987;136:357–362.
Freeland HS, Pitkorn U, Schleimer RF, et al. Leukotriene B4 as a mediator of early and late reactions to antigen in humans. The effect of systemic glucocorticoid treatment in vivo. J Allergy Clin Immunol 1989;83:634–642.
Volovitz B, Osur SL, Bernstein JM, Ogra PL. Leukotriene C4 release in upper respiratory mucosa during naturall allergy to ragweed to ragweed-sensitive children. J Allergy Clin Immunol 1988;82:414–418.
Taylor GW, Taylor I, Black P, et al. Urinary leukotriene E4 after antigen challenge and in acute asthma and allergic rhinitis. Lancet 1989;1:584–588.
Wang D, Clement P, Smitz J, DeWaele M, Derde MP. Correlations between complaints, inflammatory cells, and mediator concentrations in nasal secretions after nasal allergin challenge entering natural allergin exposure. Int Arch Allergy Immunol 1995;106:278–285.
Kaliner MA. The mediators of the early and late phases of allergic rhinitis. Adv Prostaglandin Thromboxane Leukotriene Res 1994;22:271–278.
Mygind N, Secher C, Kirkegaard J. Role of histamine and antihistamines in the nose. Eur J Respir Dis [Suppl] 1983;128:16–20.
Bisgaard H, Olsson P, Bende M. Effects of leukotriene D4 on nasal mucosal blood flow, nasal airway resistance, and nasal secretions in humans. Clin Allergy 1986;16:289–297.
Okuda M, Watase T, Mazawa A, Liu C-M. The role of leukotriene D4 in allergic rhinitis. Ann Allergy 1988;60:537–540.
Stevenson DD, Simon RA. Aspirin Sensitivity: Respiratory and Cutaneous Manifestations, in Middleton E, Reed CE, Ellis EF (eds). Allergy: Principles and Practice. 6th Edition, St. Louis, C. V. Mosby Co., 1998.
Christie PE, Tagari P, Ford-Hutchinson AW, Charlesson S, Chee P, Arm JP, Lee TH. Urinary leukotriene E4 concentrations increase after aspirin challenge in aspirin-sensitive asthmatic subjects. Am Rev Respir Dis 1991;143:1025–1029.
Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prosta glandins, and histamine into nasal secretions of aspirin-sensitive asthmatics during reactions to aspirin. Am Rev Respir Dis 1988;137:847–854.
Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, Montserrat JM, Gelp E. Release of peptide leukotriene into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65–69.
Knapp HR. Reduced allergin-induced nasal congestion and leukotriene synthesis with an orally active 5-lipoxygenase inhibitor. N Engl J Med 1990;323: 1745–1748.
Brown MS, Peters SP, Adkinson NF, Jr., et al. Arachadonic acid metabolites during nasal challenge. Arch Otolaryngol Head Neck Surg 1979;113:179–183.
Donelly AL, Glass M, Minkwitz MC, Casale TD. The leukotriene D4 receptor antagonist, ICI204,219, relieves symptoms of acute seasonal allergic rhinitis. Am J Respir Crit Care Med 151: 1734–1739.
Malstrom K, Meltzer E, Prenner B, Lu S, et al. Effects of montelukast (a leukotriene receptor antagonist), loratadine, montelukast pllus loratadine, and placebo in seasonal allergic rhinitis and conjunctivitis. J Allergy Clin Immunol 1998;101:S97 (Abstract).
Claritin (loratidine, package insert, Schering Laboratories), 1998.
Dahlen B, Nizankowska E, Azczeklik A, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1988;157:1187–1194.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Simon, R.A. The role of leukotrienes and antileukotriene agents in the pathogenesis and treatment of allergic rhinitis. Clinic Rev Allerg Immunol 17, 271–275 (1999). https://doi.org/10.1007/BF02737610
Issue Date:
DOI: https://doi.org/10.1007/BF02737610